Inflammatory Skin Diseases Classified at Molecular Level
Molecular signatures for inflammatory skin diseases can help with classification of clinically indeterminate skin rashes
Atopic Dermatitis
Living Review Compares Treatments for Atopic Dermatitis
Abrocitinib, 200 mg daily, and upadacitinib, 30 mg daily, slightly better than dupilumab, while upadacitinib, 15 mg daily is similar to dupilumab
Dupilumab Under Review for Atopic Dermatitis in Kids 5 Years and Under
The sBLA is supported by data from the phase 3 LIBERTY AD PRESCHOOL study.
January 2022: 5 Notable Drug Approvals
Review the January 2022 notable drug approvals.
Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
MPR Weekly Dose Podcast Episode 104
This week, two new approvals for atopic dermatitis; Warnings around counterfeit HIV treatments; Some US indications for Zydelig are withdrawn; CDC pediatric flu vaccine study results; And an FDA warning against certain COVID-19 antibody tests.
Cibinqo Approved for Refractory, Moderate to Severe Atopic Dermatitis
The approval was based on data from the phase 3 JADE clinical trial program, which included the JADE MONO-1, JADE MONO-2, and JADE COMPARE trials.
Rinvoq Gains FDA Approval for Atopic Dermatitis
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Adbry Approved for Moderate to Severe Atopic Dermatitis
The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD.
